Loading
Life sciences · Journal article
Journal of Nanotheranostics · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Magnetic hyperthermia (MH) is an emerging nanotheranostic strategy in which magnetic nanoparticles (MNPs) convert alternating magnetic-field (AMF) energy into localized heat for cancer treatment. This review examines how heat generation, nanoparticle design, field application, and tumor biology jointly determine therapeutic efficacy and clinical translatability. Fifty-five peer-reviewed studies, published predominantly from 2020 to 2026 and complemented by foundational work, were analyzed across four domains: heat-generation mechanisms, nanoparticle architecture and synthesis, application conditions and thermal dosimetry, and biological responses. The evidence shows that Néel and Brownian relaxation, hysteresis losses, and collective magnetic interactions are governed not only by composition, size, morphology, anisotropy, and surface chemistry but also by field amplitude, frequency, waveform, aggregation, immobilization, and intratumoral distribution. Consequently, high specific absorption rate (SAR) or intrinsic loss power (ILP) in water does not reliably predict cellular or in vivo performance. Translation requires clinically safe AMF exposure, standardized SAR/ILP measurement and reporting, scalable synthesis, validated thermal models, quantitative thermal-dose metrics, and assessment of apoptosis, necrosis, ferroptosis, lysosomal death, and antitumor immunity. MH should therefore be developed as an integrated nanotheranostic therapy that co-optimizes particle physics, field engineering, heat transfer, and tumor biology. The major focus of this review is the integrated co-optimization of nanoparticle physics, AMF engineering, heat transfer and dosimetry, and tumor biology to improve the clinical translation of magnetic hyperthermia.